Registry-listed formulations

nedosiran · mesh:C000723113

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • DCR-PHXCRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • DCR-PHXCRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • DCR-PHXCRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • DCR-PHXCRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
67%(2 trials)

Phase Distribution

Phase 2
3
50%
Phase 3
1
17%
Phase 1
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

unknown117%
active_not_recruiting117%
recruiting117%
completed350%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_3

Long Term Extension Study in Patients With Primary Hyperoxaluria

NCT04042402
completedphase_2

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

NCT05001269
recruitingphase_2

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

NCT04580420
unknown

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

NCT05993416
completedphase_1

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04042402Phase 3

Long Term Extension Study in Patients With Primary Hyperoxaluria

Active Not Recruiting
NCT05001269Phase 2

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Completed
NCT04580420Phase 2

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Recruiting
NCT05993416

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Unknown
NCT04555486Phase 1

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

Completed
NCT03847909Phase 2

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Oligonucleotide
Total Trials
6

External References

ChEMBL
CHEMBL4650244

Names & Codes

ATC Classification

A16AX25

Research Codes

DCR-PHXC FREE ACID